Sleep tech awakens the market
Sleep tech awakens the market
About this video
David Lawson, CEO of Compumedics (ASX: CMP), shares information about the company's skyrocketing sales orders, which reached a record $52 million, a leap of 22% from the prior period. Revenue has increased 16% to hit $49 million. This upward trend in figures has been largely driven by the Australian market's uptake of their SomFit device, a home sleep testing product. David also highlights two new business orders, totalling nearly $10 million. Aligned with these developments, he notes the company's strong performance as the year ends and the expected momentum in the US market.
David reveals the company's growth strategy, especially in the US, primarily leveraging the right personnel. This is evident from a recent appointment of a senior salesperson, Craig Gallivan, who previously had a successful career with a major competitor. Gallivan will drive home sleep testing business and team building to ensure growth achievement in FY 25. Regarding metrics, David mentions a target of gaining about 5 to 10% market share over 12 to 24 months in the significant home sleep testing market in the US, which at present is estimated to be worth approximately $100 million.
Finally, David sees considerable potential for continuing momentum in the market, spurred by large numbers of undiagnosed sleep disorder patients in the US. This trend is bolstered by the increasing demand for home sleep testing devices due to high-capacity sleep labs. He distinguishes Compumedics (ASX: CMP) from competitors like ResMed(ASX: RMD) by emphasising the company's focus on the diagnosis of numerous sleep disorders beyond sleep apnea. Going forward, the recently raised capital will expedite the US sales strategy for the home sleep testing market, and the future focal points comprise the home sleep testing market, the MEG business, and the core business in sleep and neurology.
Full unedited transcript below:
0:00
Back to small caps and comp. Medics yesterday posted record sales orders of approximately $52 million, up 22% on the prior period. Revenue up 16% to $49 million. So there must be a story behind those numbers. Comp Medics executive Director David Lawson joins me now. Hey David, welcome back to Orbeez. Thanks so much for joining us. So where is this momentum coming from?
0:23
Um, it's great to be here. Thanks for having me. Um, the momentum is coming from, uh, initially in the FY 24 numbers, the Australian business, uh, is up 30 odd percent this year, driven by our new, uh, song fit uh, device, which is a sleep device that, uh, is a targeted home sleep testing market. Um, also our Meg business, which is in the neurological space. Uh, We took two new orders there for close to $10 million. And those two things combined have driven, uh, the strong numbers. The, uh, good thing to note in all of that is that, uh, uh, we have a lot of momentum as we exited the year out of our US business, and that's going to be the focus, uh, for growth in FY 25. Okay. So how do you ensure that growth in the US and FY 25?
1:21
Uh, from our point of view, it's about having the right people in the right chairs. And, uh, we've spent a fair bit of time this year reorganizing our sales leadership in the US. And as we noted, to market, uh, in the middle of June, we have brought on, uh, a very senior salesperson, uh, for our home sleep testing business in the US. Craig Gallivan has joined our business. And, uh, he had a highly successful career with, uh, one of our main competitors in the US. And, uh, he loves the song fit technology. And, uh, we'll drive that business forward with him and build a team around him. Uh, to, uh, to hit our, uh, numbers in FY 25. Yeah. So how many like, do you do you think about it? And how many units need to be sold, or what is the sort of metric that investors can be looking to?
2:15
Uh, well, from our point of view, we think the best market home sleep testing market in the US is around about 2 million, uh, studies a year. It's, uh, sort of approximating half the market, uh, for home sleep testing. Um, we have a sort of target price there that would put the market at around $100 million. So from our point of view, uh, we want to carve a market percentage share out of that business with our new device. So from an investor point of view, uh, you know, we're looking to build, uh, from a virtually zero market share base to 5 to 10 plus percent over the next 12, 18, 24 months.
2:59
Okay, so there's quite some things that have to go, right. If we see a big slowing in the US economy, like how does the macro environment impact or likely impact sales? Well, from our point of view, uh, we sort of look through the cycles because, um, from wherever you look, they're at between 60 and 80 million people with some form of sleep disorder in the US, um, alone. And, uh, they're undiagnosed. Uh, we all know that sleep is one of the three pillars of health, along with, uh, good diet and exercise. Uh, so from our point of view, uh, we see the momentum in the market continuing for quite some time, driven by those large numbers of undiagnosed people in particularly in the home sleep testing space where traditionally sleep testing has been done in sleep labs. Um, those sort of labs are at capacity. And, um, that home sleep test is a much simpler, uh,
3:59
product, a screening device, if you will. And, uh, we think the undiagnosed patient population will continue to drive our business forward. So it's an interesting one, isn't it? Because I agree a good night's sleep. You know, it's so important when it comes to overall health and happiness. But we have heard in relation to all of the GLP one drugs, you know, when it comes to, say, ResMed, for example, in their sleep apnea product. So like the market keeps getting spooked that these weight loss drugs are going to lead to improved health, and therefore perhaps not as disturbed sleep. To just put it very simply, how is this any different in that regard than, say, ResMed?
4:43
Well, Company medics is focused on diagnosis over its period of time. So apnea is one of uh, uh, 89 sleep disorders. Um, yes. It's been the biggest one and it's the most common one. But there are significant other, uh, sleep disorders from restless leg syndrome, insomnia, uh, teeth grinding, just to name a few. So from our point of view, we see a large market continuing, uh, untapped market continuing for our products, and particularly the song fit device and the, uh, the devices that will follow, or the variations of that product that will follow over the year ahead.
5:26
You raised capital not too long ago. Why was that needed when you know you've got sales going well?
5:34
Uh, well, the, the, uh, capital was raised because we wanted to, uh, provide a lift to the, uh, US sales strategy for the home sleep testing market. So, um, in all cases, you can sort of do these things within the capital constraints of the business. Or you can, uh, take on some more, uh, capital so that you can do things a bit faster. And that's what we've, uh, focused on. We we think we can do things a bit faster in the, in the US market and particularly of, um, you know, our learnings in the Australian market, in our home market. Okay. And so for shareholders existing or investors future potential, what's the next catalyst to see this share price lift. Well from my point of view, I think it's continuing to focus on the three things we are focused on, which is the home sleep testing market, uh, both here in the United States. And then we'll move on to Europe and other parts of the world. Uh, with the
6:34
MLG business, uh, we have three orders, one installed at TJ and university, and, uh, we're close to, uh, starting the customer, uh, acceptance testing for that and getting sign off on that system. And I think we'll see, uh, more sales behind that, um, come to fruition over the next financial year and beyond. So, uh, to me, they're the main trigger points, along with the core business in sleep and neurology. I think in the US, we have had, um, Philips exit the market there. So there is an opportunity in our traditional sleep lab based business to outperform and grow the business. So I think those three things, uh, are things that, uh, existing and future shareholders should look out for.